Valuation: Check-Cap Ltd.

Market Cap 9.63M 8.32M 7.82M 7.11M 13.36M 921M 13.58M 91.58M 35.81M 461M 36.16M 35.37M 1.53B P/E 2024
-0.23x
P/E 2025 2.44x
Enterprise Value 9.43M 8.14M 7.65M 6.96M 13.08M 901M 13.3M 89.65M 35.05M 451M 35.39M 34.62M 1.5B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
2.02%
Yield 2024 *
-
Yield 2025 -
1 day-1.25%
1 week-11.65%
Current month+17.52%
1 month+10.24%
3 months-30.41%
6 months-32.30%
Current year-23.10%
1 week 8.33
Extreme 8.33
10.21
1 month 6.65
Extreme 6.650001
10.48
Current year 6.65
Extreme 6.650001
27.44
1 year 4.2
Extreme 4.201401
27.44
3 years 3.92
Extreme 3.920001
32.38
5 years 3.92
Extreme 3.920001
183.4
10 years 3.92
Extreme 3.920001
4,956
Manager TitleAgeSince
Chief Executive Officer 45 2024-07-16
Director of Finance/CFO 51 2025-04-05
Human Resources Officer - 2008-12-31
Director TitleAgeSince
Director/Board Member 53 2024-01-24
Chairman 45 2024-01-24
Director/Board Member 54 2024-01-24
Change 5-day change 1-year change 3-year change Capi.($)
-1.25%-11.65%+84.14%-59.82% 9.75M
+1.14%-0.76%+91.49%+295.21% 3.9B
-3.17%-12.64%+37.32%+62.66% 3.42B
+7.06%+10.09%+184.90%-1.97% 2.95B
-4.35%-2.93%+283.42%+384.97% 2.45B
-3.10%+1.70%-19.56%-26.36% 2.39B
+0.78%+11.25%+15.23%+49.19% 1.02B
-1.38%-8.51%+119.23%-43.28% 861M
-0.20%+6.38%-33.47%+0.92% 567M
+29.91%+22.82%-6.81%+358.96% 473M
Average +2.54%+0.11%+75.59%+102.05% 1.81B
Weighted average by Cap. +0.55%-0.85%+98.36%+134.28%

Financials

2024 2025
Net sales - -
Net income -25.15M -21.72M -20.41M -18.56M -34.9M -2.4B -35.48M -239M -93.51M -1.2B -94.42M -92.37M -4B 4.14M 3.58M 3.36M 3.06M 5.75M 396M 5.84M 39.37M 15.39M 198M 15.54M 15.21M 659M
Net Debt -129K -111K -105K -95.22K -179K -12.34M -182K -1.23M -480K -6.18M -484K -474K -20.53M -203K -175K -165K -150K -282K -19.41M -286K -1.93M -755K -9.72M -762K -746K -32.3M
Logo Check-Cap Ltd.
Check Cap Ltd is an Israel-based clinical-stage medical diagnostics company. Check Cap Ltd develops C-Scan, a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. Its capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps and other structural abnormalities. C-Scan is a non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.
Employees
85
Date Price Change Volume
26-08-14 US$8.720 -1.25% 28,320
26-08-13 US$8.830 -0.67% 57,447
26-08-12 US$8.890 +6.28% 18,949
26-08-11 US$8.365 -8.78% 98,868
26-08-10 US$9.170 -7.09% 12,843
  1. Stock Market
  2. Stocks
  3. MBAI Stock